For the Inventor, By the Inventor

Enter assignee name

Biontech Ag

USPTO Granted Patents = 36

CIPO Patents = 6

EPO Patents = 31

Trademarks = 1

Forward Citations = 166

Loading Chart...

Loading Chart...

67 inventors (with patents filed for the assignee):

Ugur Sahin (26 out of 182 patents)

Özlem Türeci (11 out of 52 patents)

Ozlem Tureci (11 out of 53 patents)

4. Michael Koslowski (9 out of 53 patents)

5. Gerd Helftenbein (6 out of 15 patents)

6. Volker Schlüter (6 out of 13 patents)

7. Sebastian Kreiter (5 out of 23 patents)

8. Steve Pascolo (4 out of 24 patents)

9. Jens Schumacher (4 out of 5 patents)

10. Markus Fiedler (3 out of 12 patents)

11. Dirk Usener (3 out of 19 patents)

12. Stefano Maiorana (2 out of 28 patents)

13. Thomas Michael Hiller (2 out of 6 patents)

14. Holger Hoff (2 out of 4 patents)

15. Dieter Moosmayer (2 out of 8 patents)

36 patents: Sort by Forward Citations

1. 11795218 - Diagnosis and therapy of cancer involving cancer stem cells (2023-10-24),

2. 10980875 - Cytotoxic immunostimulating particles and uses thereof (2021-04-20),

3. 10717780 - Agents for treatment of claudin expressing cancer diseases (2020-07-21),

4. 10626400 - Stabilised formulations of RNA (2020-04-21),

5. 10604568 - Diagnosis and therapy of cancer involving cancer stem cells (2020-03-31),

6. 10370433 - Compositions and methods for diagnosis and treatment of cancer (2019-08-06),

7. 10302647 - Identification of surface-associated antigens for tumor diagnosis and therapy (2019-05-28),

8. 10253373 - Identification of tumor-associated markers for diagnosis and therapy (2019-04-09),

9. 10188712 - Tumor antigens for determining cancer therapy (2019-01-29),

10. 10172960 - Particles comprising single stranded RNA and double stranded RNA for immunomodulation (2019-01-08),

11. 10106800 - Modification of RNA, producing an increased transcript stability and translation efficiency (2018-10-23),

12. 10093736 - Agents for treatment of claudin expressing cancer diseases (2018-10-09),

13. 9944708 - Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZe (antibody-mediated apoptosis inducing cytokines) (2018-04-17),

14. 9910043 - Identification of tumor-associated cell surface antigens for diagnosis and therapy (2018-03-06),

15. 9730976 - Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers (2017-08-15),

BioNTech is a pioneering biotechnology company that focuses on developing personalized cancer immunotherapies and innovative vaccines for infectious diseases. Their innovative mRNA technology platform enables the creation of new therapeutics to improve treatment options for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

36 Patents

#10 in Mainz

#1,417 in Germany

#18,179 in the World

Biontech Ag

Forward Citations = 166

67 inventors:

Ugur Sahin (26 out of 182 patents)

Özlem Türeci (11 out of 52 patents)

Ozlem Tureci (11 out of 53 patents)

4. Michael Koslowski (9 out of 53 patents)

5. Gerd Helftenbein (6 out of 15 patents)

Please report any incorrect information to support@idiyas.com

Loading…